N/A N=40 Fitting Evaluation of Hydrogel and Silicone Hydrogel Sphere Design Contact Lenses
Myopia
Primary: Visual Acuity — -0.04; -0.05; -0.03; -0.01 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=894 A Study of LY900010 in Erectile Dysfunction
Erectile Dysfunction
Primary: Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score — 2.515; 2.405; -0.971; 3.530 units on a…
N/A N=15 Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy
Hepatic Encephalopathy
Primary: Percentage of Slow Wave Sleep and REM Sleep — 56 percentage of total sleep time per 24h
Phase 4 N=18 A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease
COPD
Primary: CRP — 2.9; 2.0 mg/L
N/A N=49 Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot)
ALS
Primary: Standard PFT - Forced Vital Capacity — 72.7 Percent Predicted FVC
Phase 4 N=98 Comparability and Standardization of Controlled Allergen Challenge Facilities
Allergic Rhinitis
Primary: Comparison of TRSS From Baseline Between the EEU and BRC in the Cetirizine 10 mg and Placebo Groups. — 11.9; 11.7; 11.5; 10.8 score on a scale
N/A N=50 Psychological and Psychosocial Intervention With War-Affected Children
Stress Disorders, Post-Traumatic · Depression · Anxiety
Primary: Change in Post-traumatic Stress Symptoms as Measured by the University of California Los Angelus Post Traumatic Stress Disorder -Reaction Index — 47.77; 45.79; 21.54…
N/A N=16 Surface Stimulation for Female Sexual Dysfunction
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Phase 3 N=26 Actinic Keratoses Treatment With Metvix® in Combination With Light
Actinic Keratoses
Primary: Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12 — 19.6; 20.0 number of lesions — p=0.8460
Phase 2 N=50 MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Association of Baseline FMISO PET and MRI Features With OS as Assessed Using Cox-regression Model — 25; 22; 24; 20 Participants — p=0.048
Phase 4 N=140 Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Heart Failure, Reduced Ejection Fraction
Primary: Ratio of Mean Activity Counts Collected During the Most Active 30 Minutes of the Subject's Day Between Week 8 and Baseline — 1.0411; 0.9844 Ratio — p=0.0895
N/A N=556 Optimizing Veteran-Centered Prostate Cancer Survivorship Care
Prostate Cancer
Primary: The Expanded Prostate Cancer Index (EPIC) - Urinary Health, Irritative — 60.1; 61.4 score on a scale
N/A N=13 Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury
Spinal Cord Injury · Tetraplegia · Paresis
Primary: Grasp Release Test — 58.5; 72.0; 77.5 Objects moved — p=<0.025
Phase 2 N=43 Rituximab and Belimumab for Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event By Week 24, Week 48 and Week 96 — 9.1; 4.8; 22.7; 9.5 percentage of participants…
N/A N=62 Clinical Evaluation of an Integrated PET/MRI System
Subjects With Clinical Indication for PET/CT
Primary: Number Usable PET/MRI Image Sets — 70 Usable image sets